Unparalleled Clinical Evidence

The PKG^® system provides a continuous, objective assessment of movement disorder symptoms, such as tremor, dyskinesia and bradykinesia during activities of daily living and in the patient’s home environment. Our industry leading, clinically validated FDA Class II cleared algorithms power precision medicine for patients, clinicians and our life science partners.

Validation Studies

Automated assessment of bradykinesia and dyskinesia in Parkinson's disease. J Parkinsons Dis.

Griffiths RI, Kotschet K, Arfon S, Xu ZM, Johnson W, Drago J, Evans A,Kempster P, Raghav S, Horne MK.
2012;2(1):47-55.

Daytime sleep in Parkinson's disease measured by episodes of immobility. Feb 2014. Parkinsonism and Related Disorders.

McGregor S, Kettlewell J, Kyoong A, O’Driscoll D.M, Turton A.R, Griffiths R.I. Feb 2014.
Parkinsonism and Related Disorders. 1353-8020/ 2014 Elsevier Ltd.

conditioned response as a measure of impulsive-compulsive behaviours in Parkinson's disease.

Evans AH, Kettlewell J, McGregor S, Kotschet K, Griffiths RI, Horne M. A
PLoS One. 2014 Feb 24;9(2):e89319.doi:10.1371/journal.pone.0089319. eCollection 2014.

An Objective Fluctuation Score for Parkinson's Disease

Horne M, McGregor S, Bergquist F. 2015.
PLOS One. Apr 2015. DOI:10.1371.

The Clinical Validation of Objective Measurement of Movement in Parkinson’s Disease.

Horne M, Kotschet K, McGregor S. 2016
CNS 2016: Jun 2016. 2:(1).

An Ambulatory Tremor Score for Parkinson's Disease.

Braybrook M, O’Connor S, Churchward P, Perera T, Farzanehfar P, Horne M
J Parkinsons Dis. 2016 Oct 19;6(4):723-731.

Correlation of Quantitative Motor State Assessment Using a Kinetograph and Patient Diaries in Advanced PD: Data from an Observational Study.

Ossig C, Gandor F, Fauser M, Bosredon C, Churilov L, Reichmann H, Horne MK, Ebersbach G, Storch A
PLoS One. 2016 Aug 24;11(8):e0161559. doi: 10.1371/journal.pone.0161559. eCollection 2016.

the potential use of Parkinson's KinetiGraph: a prospective comparative study.

Klingelhoefer L, Rizos A, Sauerbier A, McGregor S, Martinez-Martin P, Reichmann H, Horne M, Chaudhuri KR. Night-time sleep in Parkinson’s disease
Eur J Neurol. 2016 Aug;23(8):1275-88. doi: 10.1111/ene.13015. Epub 2016 May 10.

The use of accelerometry as a tool to measure disturbed nocturnal sleep in Parkinson’s disease.

McGregor, Churchward, Soja, et al. (2018)
npj Parkinson’s Disease (2018) 4:1. doi:10.1038/s41531-017-0038-9.

The role of the Personal KinetiGraph ™ fluctuator score in quantifying the progression of motor fluctuations in Parkinson’s disease.

E. Tan, M. Horne, E. Hogg, P. Chang, J. Mirocha and M. Tagliati
Functional Neurology 2019; 34(1):21-28. Access at: https://www.ncbi.nlm.nih.gov/pubmed/31172936

The Use of Data from the Parkinson’s KinetiGraph to Identify Potential Candidates for Device Assisted Therapies

Khodakarami H, Farzanehfar P, Horne M.
Sensors 2019, 19, 2241; doi: 10.3390/s19102241. Access at: https://www.ncbi.nlm.nih.gov/pubmed/31096576

Prediction of the Levodopa Challenge Test in Parkinson’s Disease Using Data from a Wrist Worn Sensor.

Khodakarami H, Ricciardi L, Contarino MF, Pahwa R, Lyons K, Geraelts V, Morgante F, Leake A, Paviour D, De Angelis A, Horne M
Sensors 2019, 19(23), 5153; https://doi.org/10.3390/s19235153

A method for measuring time spent in bradykinesia and dyskinesia in people with Parkinson's disease using an ambulatory monitor.

Khodakarami H, Shokouhi N, Horne M
J Neuroeng Rehabil.

Accuracy of Step Count Estimations in Parkinson’s Disease Can Be Predicted Using Ambulatory Monitoring

Shokouhi N, Khodakarami H, Fernando C, Osborn S and Horne M (2022)
Front. Aging Neurosci. 14:904895. doi: 10.3389/fnagi.2022.904895

Clinical Utility Studies - Posters

Objective Data In Parkinson's Disease Therapy Management - A Retrospective Analysis Of The Parkinson's Kinetigraph (Pkg) Database. Value Health.

Horne M, McGregor S, Lynch P, Zoellner Y.
2015 Nov;18(7):A685. doi: 10.1016/j.jval.2015.09.2534. Epub 2015 Oct 20.

Volume 23, Supplement 1

Flisar, et al. (12):1499-507. Eur J Neurol. 2016 May.
Access at: https://www.eaneurology.org/copenhagen2016/fileadmin/user_upload/EAN_Abstract_2016.pdf

Objective movement recording in the PD patient before and after STN-DBS.

Flisar D, Piks B, Meglic B, et al.
Mov Disord. 2016;31 (suppl 2)

Quantitative assessment of advanced therapies in Parkinson’s disease using the Parkinson KinetiGraph (PKG)

Blaze RL, Tan J, Evans AH.
Mov Disord. 2016;31 (suppl 2)

Initial Deep Brain Stimulation Programming Optimization Using the Personal KinetiGraph(PKG) Movement Recording System.

Spengler D
AAN Annual Meeting. Abstract Published Online, 2016. Access at: http://n.neurology.org/content/86/16_Supplement/P3.364

Fourth World Parkinson’s Congress 2016

Price J
Access at: http://content.iospress.com/articles/journal-of-parkinsons-disease/jpd169900

Automated assessment of advanced motor Parkinson’s disease; a pilot study of the Parkinson’s KinetiGraph as an objective tool for measurement of motor fluctuations.

Bogdanova-Mihaylova P, Kavanagh N, Walsh RA.
Mov Disord. 2016;31 (suppl 2)

Effects of safinamide in patients with Parkinson’s disease measured by Parkinson’s KinetiGraph.

Suttrup I, Zentsch V, Schroeder J, et al.
Mov Disord. 2016;31 (suppl 2)

Evaluating the Clinical Efficacy of the Personal KinetiGraph Movement Recording System.

A. Fowler, K. Lyons, V. Sharma, and R. Pahwa.
Abstracts of the 21st International Congress of Parkinson’s Disease and Movement Disorders. June 2017. Volume 32, Issue Supplement S2, Pages S1–S662. Access online at: http://onlinelibrary.wiley.com/doi/10.1002/mds.v32.S2/issuetoc

Objective Measurement in Clinical Care of Patients with Parkinson’s disease: an RCT using the PKG.

Kotschet, Farzanehfar, Braybrook, Horne^.
Abstracts of the 21st International Congress of Parkinson’s Disease and Movement Disorders. June 2017. Volume 32, Issue Supplement S2, Pages S1–S662. Access online at: http://onlinelibrary.wiley.com/doi/10.1002/mds.v32.S2/issuetoc [Manuscript submitted]

Self-perception of daily performance in relation to motor performance in advanced Parkinson’s disease – Case studies

Jansa J, Piks B, Flisar D., et al.
Mov Disord. 2016;31 (suppl 2)

Objective characterization of Parkinson’s disease motor fluctuations with the Parkinson KinetiGraph – three years of experience at a movement disorder clinic.

Bergquist F, Gudmundsdottir T.
Fourth World Parkinson’s Congress 2016, P37.01

Does Parkinsons KinetiGraph (PKG) recording help in clinical decision making? A local experience.

Wilson N, Mappilakkandy R, Smith M et al.
Mov Disord. 2017;32 (supp 2)

Automated dosing schemes for administration of microtablets of levodopa for Parksinson’s disease, using wearable sensors.

homas I, Bergquist F, Johansoon D, et al.
Mov Disord. 2017; 32 (suppl 2)

Personal KinetiGraph Devices Assessing Efficacy of Continuous Enteral Carbidopa/Levodopa Infusion Therapy.

Margolesky J, Luca C.
Mov Disord. 2017;32 (suppl 2)

Objective Data in Parkinson’s Disease: A Description of Over 10,000 Parkinson’s Symptom Scores Across the World using the Personal KinetiGraph (PKG). Abstracts of the 21st International Congress of Parkinson's Disease and Movement Disorders.

P. Lynch, R. Pahwa, F. Bergquist, and M Horne.
June 2017. Volume 32, Issue Supplement S2, Pages S1–S662. Access online at: http://onlinelibrary.wiley.com/doi/10.1002/mds.v32.S2/issuetoc [Manuscript in progress]

An Evaluation of the Parkinson’s KinetiGraph (PKG) as a Tool to Support Deep Brain Stimulation Eligibility Assessment in Patients with Parkinson’s Disease. Abstracts of the 21st International Congress of Parkinson's Disease and Movement Disorders.

Horne, Volkmann, Samelli et al.
June 2017. Volume 32, Issue Supplement S2, Pages S1–S662. Access online at: http://onlinelibrary.wiley.com/doi/10.1002/mds.v32.S2/issuetoc

Personal KinetiGraph (PKG) for Parkinson Disease: Experience at a Tertiary Care Center. Abstracts of the 21st International Congress of Parkinson's Disease and Movement Disorders.

V. Sharma, A. Fowler, K. Lyons, and R. Pahwa.
June 2017. Volume 32, Issue Supplement S2, Pages S1–S662. Access online at: http://onlinelibrary.wiley.com/doi/10.1002/mds.v32.S2/issuetoc

A Global Multicenter Registry of Objective Monitoring of Parkinson’s KinetiGraph and Effect of Apomorphine: Preliminary Data from the PK-APO Study. Abstracts of the 21st International Congress of Parkinson's Disease and Movement Disorders.

M. Rosa-Grilo, G. Harington, A. Sauerbier, N. Titova, P. Odin, T. Henriksen, et al.
June 2017. Volume 32, Issue Supplement S2, Pages S1–S662. Access online at: http://onlinelibrary.wiley.com/doi/10.1002/mds.v32.S2/issuetoc

Ambulatory Movement Measurement in Evaluating Deep Brain Stimulation Effect in Patients with Advanced Parkinson’s Disease. Abstracts of the 21st International Congress of Parkinson's Disease and Movement Disorders.

M. Koivu, F. Scheperjans, and E. Pekkonen.
June 2017. Volume 32, Issue Supplement S2, Pages S1–S662. Access online at: http://onlinelibrary.wiley.com/doi/10.1002/mds.v32.S2/issuetoc

A Service Evaluation of the Clinical Use of Parkinson’s KinetiGraph (PKG) Movement Recording System in the Assessment of Parkinson’s Disease Patients with Tremor. Abstracts of the 21st International Congress of Parkinson's Disease and Movement Disorders.

J. Price, H. Martin, and L. Ebenezer.
June 2017. Volume 32, Issue Supplement S2, Pages S1–S662. Access online at: http://onlinelibrary.wiley.com/doi/10.1002/mds.v32.S2/issuetoc

Usefulness of Parkinson’s KinetiGraph recordings in the management of Parkinson’s disease.

Ulikova S.,
2017. Accessed at: https://parkinsonsacademy.co/wp-content/uploads/sites/2/2017/06/Ulikova.pdf.

Qualitative Evaluation of the Personal KinetiGraph™ Movement Recording System in a Parkinson's Clinic.

JW Langston, M Harsch, L Rees, R Dhall, R Gandhy, S Brillman, and C Barlow.
PSG Conference Abstracts. Sept 2017. Access online at: http://onlinelibrary.wiley.com/doi/10.1002/mds.27134/full

Can implementation of technology transform the management of Parkinson's? Lessons learnt from the Parkinson's KinetiGraphTM (PKGTM) service evaluation project.

C. Thomas, B. Mohammed, E. Abdelgadir, M.A Silverdale, C. Kobylecki, L. Osborne, M. Smith, A. Hulejczuk, A.R Saha, P.G Bain, C. Carroll.
PSG Conference Abstracts. Sept 2017. Access online at: http://onlinelibrary.wiley.com/doi/10.1002/mds.27134/full

Personal KinetiGraph (PKG) use in the Identification of Unknown, Under-medicated Parkinson's Disease Patients.

M. Andriola.
PSG Conference Abstracts. Sept 2017. Access online at: http://onlinelibrary.wiley.com/doi/10.1002/mds.27134/full

Personal KinetiGraph™ (PKG™) use in the Routine Clinical Care of Patients with Parkinson's Disease.

N. Thakur, L. Ramatowski.
PSG Conference Abstracts. Sept 2017. Access online at: http://onlinelibrary.wiley.com/doi/10.1002/mds.27134/full

Thirty first annual symposium on etiology, pathogenesis, and treatment of Parkinson disease and other movement disorders: Presented by the Parkinson study group, huntington study group, dystonia study group, tourette syndrome study group, cooperative ataxia group, and tremor research group.

Mov Disord. 2017 Sep;32(9):e1-e19. doi: 10.1002/mds.27134. PubMed PMID: 28887904. Poster Number 29

https://onlinelibrary.wiley.com/doi/epdf/10.1002/mds.27134

Objective Measurement in Clinical Care of Patients with Parkinson’s disease: an RCT using the PKG [abstract].

Farzanehfar, M. Braybrook, K. Kotschet, M. Horne.
Mov Disord. 2017; 32 (suppl 2). http://www.mdsabstracts.org/abstract/objective-measurement-in-clinical-care-of-patients-with-parkinsons-disease-an-rct-using-the-pkg/ Accessed December 20, 2018. [Manuscript submitted for publication.]

Objective Data in Parkinson’s Disease: A description of over 20,000 Parkinson’s symptom scores across the world using the Personal KinetiGraph (PKG) [abstract].

P. Lynch, R. Pahwa, F. Bergquist, M. Horne.
Mov Disord. 2018; 33 (suppl 2). http://www.mdsabstracts.org/abstract/objective-data-in-parkinsons-disease-a-description-of-over-20000-parkinsons-symptom-scores-across-the-world-using-the-personal-kinetigraph-pkg/. Accessed December 12, 2018

Evaluating the clinical utility of the Parkinson’s KinetiGraph (PKG) in the remote management of Parkinson’s Disease.

Dominey T, Hutchinson L, Pearson E, et al.
Mov Disord. 2018;33 (suppl 2)

Using remotely collected data to identify Parkinson’s disease subtypes.

Dominey T, Carroll C.
Mov Disord. 2018;33 (suppl 2)

Does the Parkinson’s KinetiGraph change clinical practice?

Jones S, Grose C, Mahon S, et al.
Mov Disord. 2018;33 (supp 2)

Liquid Sinemet in the management of complex, motor fluctuations in advanced Parkinson’s Disease.

Sung C, Danoudis M, Lansek R.
Mov Disord. 2018;33 (suppl 2)

Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry.

Johansson D, Ericsson A, Johansson A, et al.
Mov Disord. 2018;33 (suppl 2)

WED131 Evaluating the clinical utility of the Parkinson’s KinetiGraph (PKG).

Hutchinson L, Dominey T, Pearson E, et al.
Journal of Neurology, Neurosurgery & Psychiatry. 2018;89: A15

Clinical Experience with Personal KinetiGraph Before and After Deep Brain Stimulation for Parkinson’s Disease.

Gernon S, Fowler S, Lyons K, Pahwa.
Neurology. 2018;90 (15 Supplement) P3:045

Combined catechol-O-methyl-transferase inhibition and intrajejunal Levodopa infusion: A real-life single-centre experience.

Taddei RN, Leta V, Sauerbier A, et al.
Mov Disord. 2018;33 (suppl 2)

Personal KinetiGraph™ Movement Recording System: An Assessment of Utility in a Movement Disorder Clinic [abstract].

F. Nahab, H. Abuhussain, L. Moreno.
Mov Disord. 2018; 33 (suppl 2). http://www.mdsabstracts.org/abstract/personal-kinetigraph-movement-recording-system-an-assessment-of-utility-in-a-movement-disorder-clinic/. Accessed December 12, 2018.

West Sweden Parkinson Objective Measurement Registry Study (WestPORTS).

Bergquist F, Ax A, Sjostrom S et al.
Mov Disord. 2018;33 (suppl 2).

Amantadine extended release (Gocovri) reduces dyskinesia and bradykinesia. Evaluation of clinical response with the wearable PKG (Personal KinetiGraph) watch.

Chhabria N, Isaacson S, Lyons K et al.
Mov Disord. 2018;33 (suppl 2)

Accelerometric evaluation of motor performance in PD patients before and after STN-DBS treatment.

Flisar D, Trost M, Georgiev D, et al.
Eur J Neurol. 2018;25 (suppl 2).

Parkinson KinetiGraph – does it change the management of PD patients?

Bergquist F, Cvejkovic A, Sjostrom AC, et al.
Mov Disord. 2019;34 (suppl 2).

An Observational Study of PKG Movement Recording System Use in Routine Clinical Care of Patients with Parkinson’s Disease.

Joshi R, Bronstein JM, Alcazar J, Yang D, Joshi M, Hermanowicz N.
Movement Disorders Vol. 34: Suppl 1, p 19 © 2019 International Parkinson and Movement Disorder Society.

Continuous Objective Monitoring in Parkinson’s Disease: A description of over 25,000 Parkinson’s symptom scores across the world using the Personal KinetiGraph (PKG) wearable monitoring device.

Lynch P, Pahwa R, Bergquist F, Horne M
AAN 2019 Abstract.http://indexsmart.mirasmart.com/AAN2019/SearchResults.php?Topic=&Session_Name=&Author=Lynch%2C+Peter%3Csup%3E1%3C%2Fsup%3E&Title=

Is the Personal KinetiGraph useful in the management of Parkinson’s disease patients? A retrospective study from a tertiary movement disorders center. International Association of Parkinsonism and Related Disorders Congress Abstract.

Krause E, Randhawa J, Mehanna R
June 2019. https://www.iaprd-world-congress.com/abstract-e-book/

Parkinson’s KinetiGraph (PKD) in clinical management of Parkinson’s disease. World Parkinson’s Congress.

Rao S, Ebenezer L, Raha S.
Abstract. 2019 P25.08

THUR 122 Parkinson’s KinetiGraph improves movement disorder service provision. Journal of Neurology, Neurosurgery & Psychiatry.

Christopher K, Lucy P, Monty S.
2018;89:A13.

Does information from the Personal KinetiGraph (PKG) influence neurologists’ treatment decisions?

Sundgren M, Rousu P, Johansson A.
Mov Disord. 2019;34 (suppl 2)

Evaluation of Device-Assisted Treatment using a wearable accelerometry wrist sensor.

Johansson A, Lundgren M, Othman M et al.
Mov Disord. 2019;34 (supp 2)

Wearable sensor use and monitoring effect of dopamine replacement therapy on motor parameters in a real life clinical setting.

Podlewska A, van Wamelen D, Sauerbrier A, et al.
Mov Disord. 2019; 34 (suppl 2)

Do non-motor fluctuations temporarily match ON/OFF motor condition?

Del Prete E, Schmitt E, Meoni S, et al.
Mov Disord. 2019;34 (suppl 2)

So much easier”; patient’s perceptions of Virtual Clinics for Parkinson’s Disease.

Evans L, Mohamed B, Thomas EC.
Mov Disord. 2019;34 (suppl 2)

Daytime sleepiness in Parkinson’s disease: an indicator of impaired activities of daily living.

Caneto T, Tan J, Cruse B, et al.
Mov Disord. 2019;34 (suppl 2)

Wearable sensor (Parkinson’s KineticGraph) and dopamine transporter imaging as potential biosignature for constipation in Parkinson’s. Neurology

Van Wamelen D, Leta V, Podlewska A, et al.
2019;92 (15 Suppl) P2.8-006

Shedding light on the relationship between dyskinesia assessed by a wearable device and impulsive compulsive behavior in Parkinson’s disease.

Morgante F, de Angelis A, Siri C, et al.
Mov Disord. 2019; 34 (suppl 2)

Exploring the relationship between motor and non-motor fluctuations in Parkinson’s disease: patient’s perspective, clinician’s assessment and objective measures from a wearable device.

Leake A, de Angelis A, Horne M, et al.
Mov Disord. 2019; 34 (suppl 2)

Opicapone and levodopa-carbidopa intestinal gel infusion: a cost saving analysis in the United Kingdom.

Leta Vs, van Wamelen D, Sauerbier A, et al.
Mov Disord. 2019;34 (suppl 2)

PKG for the management of advanced Parkinson’s disease

Duja S.
Mov Disord. 2021

Clinical Utility Studies - Manuscripts

Parkinson’s Kinetigraph for Wearable Sensor Detection of Clinically Unrecognized Early-Morning Akinesia in Parkinson’s Disease: A Case Report-Based Observation

Karolina Poplawska-Domaszewicz, Naomi Limbachiya, Yue Hui Lau and Kallol Ray Chaudhuri

Effect of Pharmacist-Led Interventions on (Non)Motor Symptoms, Medication-Related Problems, and Quality of Life in Parkinson Disease Patients: A Pilot Study. Clinical Neuropharmacology .

Stuijt, C., Karapinar-Ḉarkit, F., van den Bemt, B., van Laar, T. (2018).
DOI 10.1097

Objective measurement in routine care of people with Parkinson's disease improves outcomes. NPJ Parkinsons Dis.

Farzanehfar P, Woodrow H, Braybrook M, McGregor S, Evans A, Nicklason F, Horne M.
2018 Apr 3;4:10. https://www.nature.com/articles/s41531-018-0046-4

Qualitative Evaluation of the Personal KinetiGraphTM Movement Recording System in a Parkinson's Clinic.

Santiago A, Langston JW, Gandhy R, Dhall R, Brillman S, Rees L, Barlow C.
J Parkinsons Dis. 2018 Nov 8. doi: 10.3233/JPD-181373. Access at: https://www.ncbi.nlm.nih.gov/pubmed/30412506

Levodopa Effect and Motor Function in Late Stage Parkinson’s Disease.

Rosqvist K, Horne M, Hagell P, Iwarsson S, Nilsson MH, Odin P.
J Parkinson’s Disease, 2018;8(1):59-70. Doi: 10.3233/JPD-171181.

Parkinson KinetiGraph: Are Motor Fluctuations in Parkinson Disease Related with Disease Duration? Advances in Parkinson’s Disease.

Berghuis E, Van Harten B, Van Kesteren-Biegstraaten M, et al.
2018;07:1-6.

Impact of Quantitative Assessment of Parkinson’s Disease-Associated Symptoms Using Wearable Technology on Treatment Decisions.

Carroll C, Kobylecki C, Silverdale M, Thomas C.
Journal of Parkinson’s Disease. DOI: 10.3233/JPD-191623. https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd191623.

Evaluation of Clinical Utility of the Personal KinetiGraph in the Management of Parkinson’s Disease.

Nahab FB, Abu-Hussain H, Moreno L.
Advances in Parkinson’s Disease, 8, 42-61.https://doi.org/10.4236/apd.2019.83005

An Observational Study of PKG Movement Recording System Use in Routine Clinical Care of Patients with Parkinson’s Disease.

Joshi R, Bronstein JM, Alcazar J, Yang D, Joshi M, Hermanowicz N.
Movement Disorders Front. Neurol. 01 October 2019 | https://doi.org/10.3389/fneur.2019.01027

Non-motor correlates of wrist-worn wearable sensor use in Parkinson’s disease: an exploratory analysis.

Daniel J. van Wamelen, Shweta Hota, Aleksandra Podlewska, Valentina Leta, Dhaval Trivedi, Alexandra Rizos, Miriam Parry and K. Ray Chaudhuri
npj Parkinson’s Disease (2019) 5:22; https://www.nature.com/articles/s41531-019-0094-4

Objective movement in Parkinson’s disease: a descriptive analysis of Parkinson’s symptom scores from a large population of patients across the world using the Personal KinetiGraph®.

Pahwa R, Bergquist F, Horne M.
Journal of Clinical Movement Disorders.

“Does the Response to Morning Medication Predict the ADL-Level of the Day in Parkinson’s Disease?” Hindawi, Parkinson’s Disease.

Trine Hørmann Thomsen, Troels Wesenberg Kjær , Lene Bastrup Jørgensen, Anita Haahr, and Kristian Winge.
Volume 2020, Article ID 7140984, 8 pages, https://doi.org/10.1155/2020/7140984.

A blinded, controlled trial of objective measurement in Parkinson’s disease.

Holly Woodrow, Malcolm K. Horne, Chathurini V. Fernando, Katya E. Kotschet and Treat to Target Study Group.
npj Parkinson’s Disease (2020) 6:35 ; https://doi.org/10.1038/s41531-020-00136-9

Assessment of Wearing Off in Parkinson's disease using objective measurement.

Farzanehfar P, Woodrow H, Horne M.
J Neurol. 2021 Mar;268(3):914-922. doi: 10.1007/s00415-020-10222-w. Epub 2020 Sep 15. PMID: 32935159.

Associations Between Fluctuations in Daytime Sleepiness and Motor and NonMotor Symptoms in Parkinson’s Disease.

Arja Höglund, Peter Hagell, Jan-Erik Broman, Sven Pålhagen, Kimmo Sorjonen, Sten Fredrikson, MD, Per Svenningsson.
Movement Disorders Clinical Practice 2021; 8(1): 44–50. doi: 10.1002/mdc3.13102.

Using telemedicine and wearable technology to establish a virtual clinic for people with Parkinson’s disease.

Evans L, Mohamed B,Thomas EC.
BMJ Open Quality 2020;9:e001000. doi:10.1136/bmjoq-2020-001000.

Introducing the Parkinson's KinetiGraph into Routine Parkinson's Disease Care: A 3-Year Single Centre Experience. J Parkinsons

Dominey T, Kehagia AA, Gorst T, et al.
Dis. 2020;10(4):1827-1832. doi:10.3233/JPD-202101

Comparing subjective and objective response to medications in Parkinson’s disease patients using the Personal KinetiGraph.

Krause, E.; Jaskaren, R.; Mehanna, R.
Parkinsonism and Related Disorders. 87 (2021) 105–110.

Improving Medication Regimen Recommendation for Parkinson's Disease Using Sensor Technology. Sensors (Basel).

Watts J, Khojandi A, Vasudevan R, Nahab FB, Ramdhani RA.
2021;21(10):3553. Published 2021 May 20. doi:10.3390/s21103553

Does Information from the Parkinson KinetiGraph™ (PKG) Influence the Neurologist’s Treatment Decisions?—An Observational Study in Routine Clinical Care of People with Parkinson’s Disease. J. Pers. Med.

Sundgren, M.; Andréasson, M.; Svenningsson, P.; Noori, R.-M.; Johansson, A.
2021, 11, 519. https://doi.org/ 10.3390/jpm11060519

Is Parkinson’s Kinetigraph Useful in Frail Patients with Parkinson’s Disease?. Volume Progress in Neurology and Psychiatry

Evans, L.; Mohamed, B.; Thomas, C.
2021, Volume 25, Issue 2, Pages 24-26. https://doi.org/10.1002/pnp.707

Long-term wireless streaming of neural recordings for circuit discovery and adaptive stimulation in individuals with Parkinson’s disease.

Gilron, R., Little, S., Perrone, R. et al.
Nat Biotechnol 39, 1078–1085 (2021). https://doi.org/10.1038/s41587-021-00897-5

Measurement of bradykinesia and chorea in Huntington’s Disease using ambulatory monitoring.

Kotschet et al.
Clinical Parkinsonism & Related Disorders, 8 (2023) 100179.https://doi.org/10.1016/j.prdoa.2022.100179

Cost-effectiveness analysis of the Parkinson’s KinetiGraph and clinical assessment in the management of Parkinson's Disease.

Chaudhuri et al.
Journal of Medical Economics, 25:1, 774-782, DOI: 1080/13696998.2022.2080437

Cost-effectiveness analysis of the Parkinson’s KinetiGraph and clinical assessment in the management of Parkinson's Disease.

Chaudhuri et al.
Journal of Medical Economics, 25:1, 774-782, DOI: 1080/13696998.2022.2080437

Review Articles

Can Objective Measurements Improve Treatment Outcomes in Parkinson’s Disease?

Horne M, Bergquist F.2014.
European Neurological Review, May 2014;9(1): 27–30.

Evaluation of the Parkinson's KinetiGraph in monitoring and managing Parkinson's disease.

Farzanehfar P, Horne M.
Expert Rev Med Devices. 2017 Aug;14(8):583-591. doi: 10.1080/17434440.2017.1349608. Epub 2017 Jul 6.

Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's disease.

Odin P, Chaudhuri KR, Volkmann J, Antonini A, Storch A, Dietrichs E, Pirtošek Z, Henriksen T, Horne M, Devos D, Bergquist F.
NPJ Parkinsons Dis. 2018 May 10;4:14. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945844/

Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson's disease: recommendations from an expert panel.

Pahwa R, Isaacson SH, Torres-Russotto D, Nahab F, Lynch PM, Kotschet KE.
Expert Rev Neurother. 2018 Jul 26; 1-12.

Parkinson’s Disease: Personalised Pathway of Care for Device-Aided Therapies (DAT) and the Role of Continuous Objective Monitoring (COM) Using Wearable Sensors.

Metta, V.; Batzu, L.; Leta, V.; Trivedi, D.; Powdleska, A.; Mridula, K.R.; Kukle, P.; Goyal, V.; Borgohain, R.; Chung-Faye, G.; et al.
J. Pers. Med. 2021, 11, 680. https://doi.org/10.3390/jpm11070680

We leverage the world’s largest body of clinical evidence in neurology, to create and deliver precision treatments by accelerating the research, approval, and adoption of treatments. Because we believe every person with a neurological condition deserves to live their best life every day.